PCNA and neoplasm: Following molecular study on EMT and cellular proliferation gene biomarkers also suggested that PKM2 siRNA concomitant treatment can totally abrogate the impact of UCHL1 overexpression vector on UBC tumor cells towards more proliferative, mesenchymal phenotype, which is characterized by reduced E-cadherin and increased N-cadherin, Vimentin, Ki67 and PCNA (Figure 6L, 6M).